William C Newman1, Jacob Goldberg2,3, Sergio W Guadix2,3, Samantha Brown4, Anne S Reiner4, Katherine Panageas4, Kathryn Beal5, Cameron W Brennan2, Viviane Tabar2, Robert J Young6, Nelson S Moss7. 1. Department of Neurosurgery, Louisiana State University Health Sciences, Shreveport, LA, USA. 2. Department of Neurological Surgery and Brain Metastasis Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 3. Department of Neurological Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Department of Radiation Oncology and Brain Metastasis Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Radiology and Brain Metastasis Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7. Department of Neurological Surgery and Brain Metastasis Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. mossn@mskcc.org.
Abstract
OBJECTIVE: Radiation therapy is a cornerstone of brain metastasis (BrM) management but carries the risk of radiation necrosis (RN), which can require resection for palliation or diagnosis. We sought to determine the relationship between extent of resection (EOR) of pathologically-confirmed RN and postoperative radiographic and symptomatic outcomes. METHODS: A single-center retrospective review was performed at an NCI-designated Comprehensive Cancer Center to identify all surgically-resected, previously-irradiated necrotic BrM without admixed recurrent malignancy from 2003 to 2018. Clinical, pathologic and radiographic parameters were collected. Volumetric analysis determined EOR and longitudinally evaluated perilesional T2-FLAIR signal preoperatively, postoperatively, and at 3-, 6-, 12-, and 24-months postoperatively when available. Rates of time to 50% T2-FLAIR reduction was calculated using cumulative incidence in the competing risks setting with last follow-up and death as competing events. The Spearman method was used to calculate correlation coefficients, and continuous variables for T2-FLAIR signal change, including EOR, were compared across groups. RESULTS: Forty-six patients were included. Most underwent prior stereotactic radiosurgery with or without whole-brain irradiation (N = 42, 91%). Twenty-seven operations resulted in gross-total resection (59%; GTR). For the full cohort, T2-FLAIR edema decreased by a mean of 78% by 6 months postoperatively that was durable to last follow-up (p < 0.05). EOR correlated with edema reduction at last follow-up, with significantly greater T2-FLAIR reduction with GTR versus subtotal resection (p < 0.05). Among surviving patients, a significant proportion were able to decrease their steroid use: steroid-dependency decreased from 54% preoperatively to 15% at 12 months postoperatively (p = 0.001). CONCLUSIONS: RN resection conferred both durable T2-FLAIR reduction, which correlated with EOR; and reduced steroid dependency.
OBJECTIVE: Radiation therapy is a cornerstone of brain metastasis (BrM) management but carries the risk of radiation necrosis (RN), which can require resection for palliation or diagnosis. We sought to determine the relationship between extent of resection (EOR) of pathologically-confirmed RN and postoperative radiographic and symptomatic outcomes. METHODS: A single-center retrospective review was performed at an NCI-designated Comprehensive Cancer Center to identify all surgically-resected, previously-irradiated necrotic BrM without admixed recurrent malignancy from 2003 to 2018. Clinical, pathologic and radiographic parameters were collected. Volumetric analysis determined EOR and longitudinally evaluated perilesional T2-FLAIR signal preoperatively, postoperatively, and at 3-, 6-, 12-, and 24-months postoperatively when available. Rates of time to 50% T2-FLAIR reduction was calculated using cumulative incidence in the competing risks setting with last follow-up and death as competing events. The Spearman method was used to calculate correlation coefficients, and continuous variables for T2-FLAIR signal change, including EOR, were compared across groups. RESULTS: Forty-six patients were included. Most underwent prior stereotactic radiosurgery with or without whole-brain irradiation (N = 42, 91%). Twenty-seven operations resulted in gross-total resection (59%; GTR). For the full cohort, T2-FLAIR edema decreased by a mean of 78% by 6 months postoperatively that was durable to last follow-up (p < 0.05). EOR correlated with edema reduction at last follow-up, with significantly greater T2-FLAIR reduction with GTR versus subtotal resection (p < 0.05). Among surviving patients, a significant proportion were able to decrease their steroid use: steroid-dependency decreased from 54% preoperatively to 15% at 12 months postoperatively (p = 0.001). CONCLUSIONS: RN resection conferred both durable T2-FLAIR reduction, which correlated with EOR; and reduced steroid dependency.
Authors: Gazanfar Rahmathulla; Pablo F Recinos; Jose E Valerio; Sam Chao; Gene H Barnett Journal: Stereotact Funct Neurosurg Date: 2012-06-05 Impact factor: 1.875
Authors: Brian J Blonigen; Ryan D Steinmetz; Linda Levin; Michael A Lamba; Ronald E Warnick; John C Breneman Journal: Int J Radiat Oncol Biol Phys Date: 2009-09-23 Impact factor: 7.038
Authors: Evan D Bander; Melissa Yuan; Anne S Reiner; Katherine S Panageas; Åse M Ballangrud; Cameron W Brennan; Kathryn Beal; Viviane Tabar; Nelson S Moss Journal: Neurooncol Pract Date: 2021-01-21
Authors: Evan D Bander; Melissa Yuan; Joseph A Carnevale; Anne S Reiner; Katherine S Panageas; Michael A Postow; Viviane Tabar; Nelson S Moss Journal: Cancer Date: 2021-03-02 Impact factor: 6.921
Authors: Gokoulakrichenane Loganadane; Frédéric Dhermain; Guillaume Louvel; Paul Kauv; Eric Deutsch; Cécile Le Péchoux; Antonin Levy Journal: Front Oncol Date: 2018-09-05 Impact factor: 6.244
Authors: Amber J Giles; Marsha-Kay N D Hutchinson; Heather M Sonnemann; Jinkyu Jung; Peter E Fecci; Nivedita M Ratnam; Wei Zhang; Hua Song; Rolanda Bailey; Dionne Davis; Caitlin M Reid; Deric M Park; Mark R Gilbert Journal: J Immunother Cancer Date: 2018-06-11 Impact factor: 13.751
Authors: Denise Bernhardt; Laila König; Anca-L Grosu; Stefan Rieken; Sandro M Krieg; Wolfgang Wick; Benedikt Wiestler; Friederike Schmidt-Graf; Felix Sahm; Jens Gempt; Bernhard Meyer; Bernd J Krause; Cordula Petersen; Rainer Fietkau; Michael Thomas; Frank Giordano; Andrea Wittig-Sauerwein; Jürgen Debus; Ghazaleh Tabatabai; Peter Hau; Joachim Steinbach; Stephanie E Combs Journal: Strahlenther Onkol Date: 2022-08-29 Impact factor: 4.033
Authors: Joseph A Carnevale; Brandon S Imber; Graham M Winston; Jacob L Goldberg; Ase Ballangrud; Cameron W Brennan; Kathryn Beal; Viviane Tabar; Nelson S Moss Journal: J Neurosurg Date: 2021-09-10 Impact factor: 5.408
Authors: Brandon S Imber; Robert J Young; Kathryn Beal; Anne S Reiner; Alexandra M Giantini-Larsen; Simone Krebs; Jonathan T Yang; David Aramburu-Nunez; Gil'ad N Cohen; Cameron Brennan; Viviane Tabar; Nelson S Moss Journal: J Neurooncol Date: 2022-07-27 Impact factor: 4.506
Authors: Alyssa Y Li; Karolina Gaebe; Katarzyna J Jerzak; Parneet K Cheema; Arjun Sahgal; Sunit Das Journal: Front Oncol Date: 2022-03-07 Impact factor: 6.244